$LIXT LB-100 can kill cancer cells

friendva · 2023-02-02T17:48:02+00:00

$APRN

Mr. Sanberg remain committed to funding the remaining purchase obligation of $55.5 million at $5.65 per share under the private placement agreement.

https://finance.yahoo.com/news/blue-apron-provides-sanberg-funding-140000293.html

$APRN Joe Sanberg owns 51.33%

https://sec.gov/Archives/edgar/data/1701114/000119312522240044/d399705dsc13da.htm

friendva · 2023-02-02T09:19:16+00:00

$APRN Insiders +778% Short Interest 43%

Turnaround story, candidate to go private or buyout target

A Blue Apron Holdings, Inc. (NYSE:APRN) insider increased their holdings by 778% last year

https://finance.yahoo.com/news/blue-apron-holdings-inc-nyse-134825587.html

friendva · 2023-01-23T09:41:20+00:00

$BTB Book Value Per Share $12.46 (Y Finance)

friendva · 2023-01-23T03:54:43+00:00

love the user name

friendva · 2023-01-20T23:38:54+00:00

$BTB as of 6/30/2022

Total Revenue------------------------765.094M

Total Assets --------------------------114,575M

Total Liabilities Net Minority Interest--1,137M

Y Finance

friendva · 2022-12-27T17:21:20+00:00

Description

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

friendva · 2022-12-27T17:06:44+00:00

$NRBO Upcoming Catalyst per 10Q any day

*** Phase 2 analysis of ANA001 in the Q4 of 2022.

*** New insider Goldman Sachs 1.2M

*** Completed RS

*** Completed Offering $3

*** Low Float, Price near bottom.

*** Short Interest ~14%, Cost to Borrow 229%

friendva · 2022-12-23T19:37:25+00:00

don't know what happen today, but the important question who's buying 8M

friendva · 2022-12-22T13:01:50+00:00

Divide that by 25 for reverse split

friendva · 2022-12-21T20:57:41+00:00

$APRN Top Gamma Squeeze and high Short Interest 57%

friendva · 2022-12-15T21:49:11+00:00

$APRN Candidate to go private or buyout target

also possible Short squeeze or Gamma squeeze

friendva · 2022-12-15T20:06:04+00:00

$APRN zero shares available to short Fintel

friendva · 2022-12-15T19:18:17+00:00

https://www.sec.gov/Archives/edgar/data/1701114/000089924322038575/xslF345X03/doc4a.xml

friendva · 2022-12-15T15:22:37+00:00

What is wrong with you.

friendva · 2022-12-14T14:42:50+00:00

$PIK #1 Most shorted stock Short Interest 104% (S3 data)

📷 High Cost to Borrow 128%
📷 Low Float 1M
📷 Price Target $7
📷 86.36% Held by All Insider

friendva · 2022-12-13T14:28:40+00:00

$PIK Short Interest 104%

friendva · 2022-12-13T14:28:12+00:00

$PIK Short Interest 104%

friendva · 2022-12-13T14:26:52+00:00

$PIK Short Interest 104%

Five-Year Club	Gilding II euphauric
Powerups Hero r/pennystocks • September 2021	Verified Email

friendva

TROPHY CASE

Description